NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido

The FDA approved Novartis’ Rhapsido for symptomatic dermographism, expanding the drug’s potential role in the company’s chronic hives opportunity. The approval offers a growth opportunity as pipeline setbacks increase pressure on Novartis, though the article provides no financial estimates or market reaction.